marked.bio

FGFR2/3-selective inhibitor · small molecule

ABSK061

1 active trials across 2 of our biomarkers, targeting FGFR2/3. Not approved for any biomarker on marked.bio yet.

Counts only trials that select patients by one of the biomarkers on marked.bio, not every trial of this drug.

Biomarkers

BiomarkerActive trialsAll trialsFurthest active phase
FGFR2 fusion or rearrangement 1 2 Phase 2
FGFR3 alteration (mutation or fusion) 1 2 Phase 2

Sponsors

Industry sponsors leading active biomarker-selected trials of ABSK061.

  1. Abbisko Therapeutics 1

Trials

1 of 2 trials shown

  1. A Phase 2 Clinical Study of ABSK061 and ABSK043

    Recruiting Phase 2 Abbisko Therapeutics Started 2024Primary completion 2029-11 NCT06632262

    ABSK061CAPOX

    …cified a central laboratory or previous test report confirming the presence of a specific FGFR3 mutation or overexpression, FGFR2/3 fusion in tumor tissue or blood based on central laboratory te…

    FGFR3 alteration (mutation or fusion)FGFR2 fusion or rearrangementHER2-Gastric/Gastroesophageal Junction Cancer, Urothelial Carcinoma, Non-Small Cell Lung Cancer, Solid Tumors